FIG. 1A



HCC827-ER1
% Viability
125
100
75
50
25
0
-5
-4
-3
-2
-1
0
1
2
Log concentration (μM)
GH21001 (TNO-155)
GH21005 (HBI-2376)
RMC-4550
Osimertinib
Cisplatin

FIG. 1B



NCI-H1975 (L858R/T790M/C797S)
% Viability
125
100
75
50
25
0
-5
-4
-3
-2
-1
0
1
2
Log concentration (μM)
GH21001 (TNO-155)
GH21005 (HBI-2376)
RMC-4550
Osimertinib
Cisplatin

FIG. 2A



HCC827_ER1
Tumor Volume (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
40
Days of dosing
Dosing stopped
Group 1 Vehicle
Group 02 HBI-2376 10 mg/kg
Group 03 Osimertinib 5mg/kg
Group 04 RMC-4550 10 mg/kg
Group 05 Osimertinib+HBI-2376
Group 06 Osimertinib+RMC-4550

FIG. 2B



Body weight
Body weight (g)
30
25
20
0
10
20
30
40
Days of treatment
(Last day of treatment, Day 18)
Dosing stopped
Group 1 Vehicle
Group 02 HBI-2376 10 mg/kg
Group 03 Osimertinib 5mg/kg
Group 04 RMC-4550 10 mg/kg
Group 05 Osimertinib+HBI-2376
Group 06 Osimertinib+RMC-4550

FIG. 3

-IHC on whole tumor analyzed using HALO software. 3 tumors per group






FIG. 4




One tumor represented for each group

FIG. 5




HCC827_ER1:pERK Western Blot (2 hours post dose) 1st set of tumors (1-4)

FIG. 6



HCC827_ER1:pERK Western Blot (2 hours post dose) 2nd set of tumors (4-8)

FIG. 7



HCC827_ER1 Study pERK Western Blot quantification

FIG. 8



G1
G2
MIA PaCa-2
5025
5057
5047
5060
5065
5066
5068
5074
5023
5062
5070
5076
5051
5063
5071
5072
DUSP6
β-actin
Group 1 Vehicle
Group 02 HBI-2376 10 mg/kg
Group 03 Osimertinib 5mg/kg
Group 04 RMC-4550 10 mg/kg

FIG. 9



DUSP6/β-actin in HCC827-ER1 CDX tumors
Normalized DUSP6/β-actin
1.5
1.0
0.5
0.0
MIA PaCa-2
G1
G2

FIG. 10A

Group 1
(5037, 5047, 5065)




FIG. 10B

Group 2
(5043, 5051, 5063)




FIG. 10C

Group 3
(5070, 5082, 5088)




FIG. 10D

Group 4
(5055, 5068, 5087)

